Gefapixant is a P2X3 receptor antagonist that has shown promise for the treatment of refractory and unexplained chronic cough. The aim of this study was to evaluate the efficacy of gefapixant compared with placebo after 12 weeks of treatment for refractory chronic cough or unexplained chronic cough.
Gefapixant, a P2X3 receptor antagonis... - Lung Conditions C...
Gefapixant, a P2X3 receptor antagonist, for the treatment of unexplained chronic cough.
Written by
2greys
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
Promising. And interesting to see that the lowest dose has almost exactly the same result as the placebo 🤔
Not what you're looking for?
You may also like...
Cystic fibrosis
HiI was diagnosed with bronchiectasis at the beginning of the year, at the time it was mentioned i...
anyone having croaky throat problems with inhalers
i’m currently using Trimbow inhaler for COPD and unfortunately, I seem to be one in 10 people...
Blood thinners advice
Morning friends, on Thursday I had a third tachycardia episode - with the previous two my heart...
My first attempt at drawing with pencils for a few years ... Its the front elevation of Beaulieu palace 🙉
It's taken a while many rubbers many ripped up pages just something a little different from me...
abit nervous 😕
Relvar/trelegy 
new on here cpoder
Hello from Chom 🐕
Easyhaler Salbutamol Sulfate inhaler
